Cargando…

Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors

Epithelial ovarian cancers (EOCs) are a heterogeneous collection of malignancies, each with their own developmental origin, clinical behavior and molecular profile. With less than 5% of EOC cases, mucinous ovarian carcinoma is a rare form with a poor prognosis and a 5-year survival of 11% for advanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Dolivet, Enora, Gaichies, Léopold, Jeanne, Corinne, Bazille, Céline, Briand, Mélanie, Vernon, Mégane, Giffard, Florence, Leprêtre, Frédéric, Poulain, Laurent, Denoyelle, Christophe, Vigneron, Nicolas, Fauvet, Raffaèle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649586/
https://www.ncbi.nlm.nih.gov/pubmed/37958997
http://dx.doi.org/10.3390/ijms242116016
_version_ 1785135586192916480
author Dolivet, Enora
Gaichies, Léopold
Jeanne, Corinne
Bazille, Céline
Briand, Mélanie
Vernon, Mégane
Giffard, Florence
Leprêtre, Frédéric
Poulain, Laurent
Denoyelle, Christophe
Vigneron, Nicolas
Fauvet, Raffaèle
author_facet Dolivet, Enora
Gaichies, Léopold
Jeanne, Corinne
Bazille, Céline
Briand, Mélanie
Vernon, Mégane
Giffard, Florence
Leprêtre, Frédéric
Poulain, Laurent
Denoyelle, Christophe
Vigneron, Nicolas
Fauvet, Raffaèle
author_sort Dolivet, Enora
collection PubMed
description Epithelial ovarian cancers (EOCs) are a heterogeneous collection of malignancies, each with their own developmental origin, clinical behavior and molecular profile. With less than 5% of EOC cases, mucinous ovarian carcinoma is a rare form with a poor prognosis and a 5-year survival of 11% for advanced stages (III/IV). At the early stages, these malignant forms are clinically difficult to distinguish from borderline (15%) and benign (80%) forms with a better prognosis due to the large size and heterogeneity of mucinous tumors. Improving their diagnosis is therefore a challenge with regard to the risk of under-treating a malignant form or of unnecessarily undertaking radical surgical excision. The involvement of microRNAs (miRNAs) in tumor progression and their potential as biomarkers of diagnosis are becoming increasingly recognized. In this study, the comparison of miRNA microarray expression profiles between malignant and borderline tumor FFPE samples identified 10 down-regulated and 5 up-regulated malignant miRNAs, which were validated by individual RT-qPCR. To overcome normalization issues and to improve the accuracy of the results, a ratio analysis combining paired up-regulated and down-regulated miRNAs was performed. Although 21/50 miRNA expression ratios were significantly different between malignant and borderline tumor samples, any ratio could perfectly discriminate the two groups. However, a combination of 14 pairs of miRNA ratios (double ratio) showed high discriminatory potential, with 100% of accuracy in distinguishing malignant and borderline ovarian tumors, which suggests that miRNAs may hold significant clinical potential as a diagnostic tool. In summary, these ratio miRNA-based signatures may help to improve the precision of histological diagnosis, likely to provide a preoperative diagnosis in order to adapt surgical procedures.
format Online
Article
Text
id pubmed-10649586
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-106495862023-11-06 Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors Dolivet, Enora Gaichies, Léopold Jeanne, Corinne Bazille, Céline Briand, Mélanie Vernon, Mégane Giffard, Florence Leprêtre, Frédéric Poulain, Laurent Denoyelle, Christophe Vigneron, Nicolas Fauvet, Raffaèle Int J Mol Sci Article Epithelial ovarian cancers (EOCs) are a heterogeneous collection of malignancies, each with their own developmental origin, clinical behavior and molecular profile. With less than 5% of EOC cases, mucinous ovarian carcinoma is a rare form with a poor prognosis and a 5-year survival of 11% for advanced stages (III/IV). At the early stages, these malignant forms are clinically difficult to distinguish from borderline (15%) and benign (80%) forms with a better prognosis due to the large size and heterogeneity of mucinous tumors. Improving their diagnosis is therefore a challenge with regard to the risk of under-treating a malignant form or of unnecessarily undertaking radical surgical excision. The involvement of microRNAs (miRNAs) in tumor progression and their potential as biomarkers of diagnosis are becoming increasingly recognized. In this study, the comparison of miRNA microarray expression profiles between malignant and borderline tumor FFPE samples identified 10 down-regulated and 5 up-regulated malignant miRNAs, which were validated by individual RT-qPCR. To overcome normalization issues and to improve the accuracy of the results, a ratio analysis combining paired up-regulated and down-regulated miRNAs was performed. Although 21/50 miRNA expression ratios were significantly different between malignant and borderline tumor samples, any ratio could perfectly discriminate the two groups. However, a combination of 14 pairs of miRNA ratios (double ratio) showed high discriminatory potential, with 100% of accuracy in distinguishing malignant and borderline ovarian tumors, which suggests that miRNAs may hold significant clinical potential as a diagnostic tool. In summary, these ratio miRNA-based signatures may help to improve the precision of histological diagnosis, likely to provide a preoperative diagnosis in order to adapt surgical procedures. MDPI 2023-11-06 /pmc/articles/PMC10649586/ /pubmed/37958997 http://dx.doi.org/10.3390/ijms242116016 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Dolivet, Enora
Gaichies, Léopold
Jeanne, Corinne
Bazille, Céline
Briand, Mélanie
Vernon, Mégane
Giffard, Florence
Leprêtre, Frédéric
Poulain, Laurent
Denoyelle, Christophe
Vigneron, Nicolas
Fauvet, Raffaèle
Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors
title Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors
title_full Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors
title_fullStr Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors
title_full_unstemmed Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors
title_short Synergy of the microRNA Ratio as a Promising Diagnosis Biomarker for Mucinous Borderline and Malignant Ovarian Tumors
title_sort synergy of the microrna ratio as a promising diagnosis biomarker for mucinous borderline and malignant ovarian tumors
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10649586/
https://www.ncbi.nlm.nih.gov/pubmed/37958997
http://dx.doi.org/10.3390/ijms242116016
work_keys_str_mv AT dolivetenora synergyofthemicrornaratioasapromisingdiagnosisbiomarkerformucinousborderlineandmalignantovariantumors
AT gaichiesleopold synergyofthemicrornaratioasapromisingdiagnosisbiomarkerformucinousborderlineandmalignantovariantumors
AT jeannecorinne synergyofthemicrornaratioasapromisingdiagnosisbiomarkerformucinousborderlineandmalignantovariantumors
AT bazilleceline synergyofthemicrornaratioasapromisingdiagnosisbiomarkerformucinousborderlineandmalignantovariantumors
AT briandmelanie synergyofthemicrornaratioasapromisingdiagnosisbiomarkerformucinousborderlineandmalignantovariantumors
AT vernonmegane synergyofthemicrornaratioasapromisingdiagnosisbiomarkerformucinousborderlineandmalignantovariantumors
AT giffardflorence synergyofthemicrornaratioasapromisingdiagnosisbiomarkerformucinousborderlineandmalignantovariantumors
AT lepretrefrederic synergyofthemicrornaratioasapromisingdiagnosisbiomarkerformucinousborderlineandmalignantovariantumors
AT poulainlaurent synergyofthemicrornaratioasapromisingdiagnosisbiomarkerformucinousborderlineandmalignantovariantumors
AT denoyellechristophe synergyofthemicrornaratioasapromisingdiagnosisbiomarkerformucinousborderlineandmalignantovariantumors
AT vigneronnicolas synergyofthemicrornaratioasapromisingdiagnosisbiomarkerformucinousborderlineandmalignantovariantumors
AT fauvetraffaele synergyofthemicrornaratioasapromisingdiagnosisbiomarkerformucinousborderlineandmalignantovariantumors